Latest Period
Q1 2026
Security Snapshot
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) Institutional Ownership
CUSIP: 483497103
13F Institutional Holders and Ownership History from Q4 2016 to Q1 2026
Institutions Reporting
181
Shares (Excl. Options)
69,229,554
Price
$20.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- KALV on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 69,229,554
- Total 13F value
- $1,392,422,058
- Portfolio coverage rank
- 0.01%
- Share change
- +1,921,513
- Value change
- +$43,302,606
- Number of holders
- 181
- Shares outstanding
- 54,311,522
- SEC-reported price per share
- $26.73
- Insider filing price
- $26.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KALV - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 483497103.
- 181 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 162 to 181 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,081,342,912 to $1,392,422,058.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 181 institutions filings for Q1 2026.
Security key
483497103
Latest holder period
Q1 2026
13F holders
181
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
KALV full holder history
KalVista Pharmaceuticals, Inc. SEC filings
KalVista Pharmaceuticals, Inc. company facts
KalVista Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 483497103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
KALV
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.9% | $63,650,358 | 4,941,798 | TANG CAPITAL MANAGEMENT, LLC | 31 Mar 2025 | |||
| Capital World Investors | 6.4% | $40,927,321 | 3,177,587 | Capital World Investors | 31 Mar 2025 | |||
| Point72 Asset Management, L.P. | 4.2% | -22% | $42,995,233 | -$12,976,635 | 2,136,940 | -23% | Point72 Asset Management, L.P. | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC | 3.7% | -37% | $38,472,378 | -$21,157,246 | 1,912,146 | -35% | Millennium Management LLC | 31 Mar 2026 |
| Frazier Life Sciences Public Fund, L.P. | 2.3% | -66% | $33,315,231 | -$59,136,885 | 1,249,165 | -64% | Frazier Life Sciences Public Fund, L.P. | 19 May 2026 |
| Vestal Point Capital, LP | 1.5% | $9,135,000 | 750,000 | Vestal Point Capital, LP | 30 Sep 2025 |
As of 31 Mar 2026, 181 institutional investors reported holding 69,229,554 shares of KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV). This represents 127% of the company’s total 54,311,522 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
102%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | 12% | 6,474,485 | -3.8% | 4.9% | $130,331,383 |
| Frazier Life Sciences Management, L.P. | 9.1% | 4,961,108 | -1.6% | 2.6% | $99,867,104 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 8.8% | 4,768,712 | 0% | 2.6% | $95,994,173 |
| TANG CAPITAL MANAGEMENT LLC | 8.4% | 4,573,530 | 0% | 4.7% | $92,065,159 |
| BlackRock, Inc. | 7% | 3,795,897 | +1.1% | 0% | $76,411,406 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 5.3% | 2,876,407 | +19% | 6.8% | $57,902,073 |
| Capital World Investors | 5.2% | 2,808,583 | 0% | 0.01% | $56,536,776 |
| Point72 Asset Management, L.P. | 3.9% | 2,136,940 | -6.4% | 0.07% | $43,016,602 |
| STATE STREET CORP | 3.6% | 1,955,844 | +2.3% | 0% | $39,371,140 |
| MILLENNIUM MANAGEMENT LLC | 3.5% | 1,912,146 | -34% | 0.03% | $38,491,499 |
| Vestal Point Capital, LP | 3.4% | 1,850,000 | -2.1% | 1% | $37,240,500 |
| Parkman Healthcare Partners LLC | 3.4% | 1,835,506 | +3.8% | 3.8% | $36,948,736 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 1,830,467 | 0% | 0% | $36,847,301 |
| Kynam Capital Management, LP | 3.4% | 1,820,954 | +0.55% | 2.3% | $36,655,804 |
| Woodline Partners LP | 2.8% | 1,509,920 | -21% | 0.11% | $30,394,690 |
| Octagon Capital Advisors LP | 2.7% | 1,450,000 | +14% | 3.2% | $29,188,500 |
| EMERALD ADVISERS, LLC | 2.3% | 1,264,023 | -5.7% | 0.81% | $25,444,783 |
| ARMISTICE CAPITAL, LLC | 2.3% | 1,236,000 | +54% | 0.82% | $24,880,680 |
| Elmind Capital, LP | 1.9% | 1,021,300 | +27% | 5.8% | $20,558,769 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 996,235 | +5.5% | 0% | $20,059,823 |
| Squadron Capital Management LLC | 1.8% | 985,100 | +41% | 7.9% | $19,830,063 |
| Spruce Street Capital LP | 1.7% | 897,681 | +131% | 4.3% | $18,070,319 |
| Freestone Grove Partners LP | 1.6% | 882,906 | +39% | 0.13% | $17,772,898 |
| GOLDMAN SACHS GROUP INC | 1.5% | 824,293 | -1.3% | 0% | $16,593,018 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1.5% | 805,762 | -5.8% | 0.79% | $16,219,989 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
38
Latest
Q1 2026
Rows shown
1-25 of 38
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 69,229,554 | $1,392,422,058 | +$43,302,606 | $20.13 | 181 |
| 2025 Q4 | 66,955,522 | $1,081,342,912 | +$110,817,109 | $16.15 | 162 |
| 2025 Q3 | 58,620,381 | $714,026,876 | +$51,785,657 | $12.18 | 143 |
| 2025 Q2 | 54,445,883 | $615,513,091 | -$5,352,606 | $11.30 | 138 |
| 2025 Q1 | 54,890,685 | $633,782,153 | +$5,364,849 | $11.54 | 127 |
| 2024 Q4 | 55,190,249 | $467,414,520 | +$30,397,001 | $8.47 | 129 |
| 2024 Q3 | 48,412,221 | $560,958,769 | +$549,019 | $11.58 | 120 |
| 2024 Q2 | 48,235,227 | $568,211,775 | +$14,329,598 | $11.78 | 118 |
| 2024 Q1 | 46,978,393 | $557,162,578 | +$117,921,974 | $11.86 | 128 |
| 2023 Q4 | 36,983,052 | $453,043,903 | +$5,790,575 | $12.25 | 92 |
| 2023 Q3 | 36,263,336 | $349,220,877 | +$17,912,528 | $9.63 | 101 |
| 2023 Q2 | 34,451,516 | $310,062,547 | +$8,864,955 | $9.00 | 93 |
| 2023 Q1 | 33,720,468 | $265,039,035 | -$7,240,065 | $7.86 | 87 |
| 2022 Q4 | 33,810,837 | $228,557,857 | +$23,549,577 | $6.76 | 88 |
| 2022 Q3 | 25,639,454 | $372,024,783 | +$16,611,056 | $14.51 | 88 |
| 2022 Q2 | 24,252,971 | $238,647,172 | -$18,209,799 | $9.84 | 84 |
| 2022 Q1 | 23,950,478 | $353,046,504 | -$11,733,222 | $14.74 | 84 |
| 2021 Q4 | 23,784,064 | $314,614,009 | -$24,155,895 | $13.23 | 93 |
| 2021 Q3 | 23,380,949 | $408,241,803 | -$21,548,932 | $17.45 | 101 |
| 2021 Q2 | 24,320,398 | $582,722,986 | +$12,095,008 | $23.96 | 108 |
| 2021 Q1 | 23,504,843 | $603,806,496 | +$241,335,972 | $25.69 | 115 |
| 2020 Q4 | 14,665,664 | $278,488,932 | +$4,362,596 | $18.99 | 79 |
| 2020 Q3 | 16,200,799 | $203,913,450 | +$2,818,589 | $12.59 | 61 |
| 2020 Q2 | 15,986,858 | $193,667,544 | +$9,419,888 | $12.10 | 72 |
| 2020 Q1 | 15,660,431 | $119,795,221 | +$17,243,054 | $7.65 | 68 |